Research article - JOBB - Journal of Biotechnology and Biosafety
Transcription
Research article - JOBB - Journal of Biotechnology and Biosafety
Journal of Biotechnology and Biosafety Volume 3, Issue 2, March-April 2015,209-213 ISSN 2322-0406 Journal of Biotechnology and Biosafety Research article Accessibility of Altered Trade Names of Ranitidine in different standard by UV Spectrophotometric Technique ______________________________________ ABSTRACT Safila Naveed1, Fatima Qamar1,Syeda Sarah Abbas1,2, Sehrish Batool3, Syed Hameez Jawed2 & Syeda Zainab2 Ranitidine lies under the group of drugs called H2 blockers. Ranitidine reduces the quantity of acid produced by the stomach. It’s used in the treatment and prevention of ulcers in stomach and in intestine like GERD & Zollinger-Ellison syndrome. Ranitidine is also coupled with enhance the risk of developing pneumonia. Assay was done by different brands available in market of ranitidine. Different dilutions were made and check out their linearity and regression was found to be linear. Absorbance was measured by UV Spectrophotometer and statistically one way ANOVA was implemented to analyze the comparison b/w groups and within groups. __________________________________________ 1 Faculty of Pharmacy, Jinnah University for women Karachi 2 Faculty of Pharmacy, University of Karachi 3 Faculty of Pharmacy, Federal Urdu University Corresponding Author Email: [email protected], [email protected] KEYWORDS: Ranitidine, GERD, UV Spectrophotometer, H2 blockers ______________________________________________________________________________ INTRODUCTION: Ranitidine is very common histamine H2 receptor antagonist .It employs protuberant results on acid secretions and less insightful outcomes on acid production (Hoogerwerf WA, Pasricha PJ 2001, Higuchi K et al 1994). Ranitidine normally used in the treatment of Gastro esophageal reflux disease (GERD), peptic ulcer, Zollinger-Ellison syndrome and similar kind of disorders. It has trivial side effects like headache, somnolence or gastrointestinal adverse effects and a very low occurrence of anaphylactic reactions so it is very well tolerated drug. Nevertheless both intravenous and oral infusions have remained seldom with intense allergic reaction such as toxic epidermal necrolysis, www.jobb.co.in exanthematous pustulosis, ultraviolet UVB and bronchospastic reactions (Martínez AJ et al 2006). Pharmacokinetics of ranitidine have been described after oral administration the 50% of ranitidine is absorbed hence the peak serum concentration is about 2± 3 hour after its dosing monitored by elimination with a half-life of 2.5±3 hours, ranitidine is metabolized to very small extent primarily by flavin mono-oxygenases (Grant SM et al.1989, PérezGuillé G et al.2005, Flores Pérez J et al 2003, Chung WG et al 2000). Elimination of ranitidine is through kidney with about 70% of the systemically dose improved in urine in the form of unchanged drug (Nwokolo CU et al.1989 Benet LZ.1991) International, Peer reviewed, Open access, Bimonthly Online Journal Journal of Biotechnology and Biosafety Volume 3, Issue 2, March-April 2015,209-213 ISSN 2322-0406 Journal of Biotechnology and Biosafety Fig-1 structure of Ranitidine EXPERIMENTAL PROCEDURE UV visible 1601 Shimadzu double beam spectrophotometer was used.Water was used as a solvent to perform this assay. Wavelength Selection About 200ppm of Ranitidine solution was accurately prepared in water. Now it was scanned in 200-400nm of UV regions. The wavelength maxima (λmax) were observed at 313nm and this wavelength was adopted for absorbance measurement. Buffer preparation pH 1 Buffer was prepared by taking 9.1mL hydrochloric acid of analytical grade (36%, 11N) in a liter volumetric flask and the volume was made up to the mark with deionized water. Buffer pH 4 (chloride buffer) by simple method by taking 0.1M hydrochloric acid and then 0.1M potassium chloride solutions was added until the appropriate pH was attained. Buffer pH 6.9: 10mM phosphoric acid (sodium) buffer solution Sodium dihydrogen phosphate dihydrate (M.W =156.01). 5mmol (0.78g) Sodium dihydrogen phosphate 12-hydrate M.W =358.14) 5 mol 1.79 g. include water to create up to 1 L Sample solution preparation 20 tablets of each brand of Ranitidine from the marketed sample were weighed and crushed homogeneously in mortar and pestle. Average weighed sample powder was equivalent to 10mg of Ranitidine and was transferred www.jobb.co.in into a volumetric flask contain 10mL of water. Sonication was done for about 5 min and then make up the volume up to 50 ml of water. The same procedure was repeated for making the solution of Ranitidine in different buffer system. (Safila Naveed et al., 2014, Safila Naveed et al., 2015) Procedure After preparation of sample solutions absorbance of the sample preparation in 1cm cell at the wavelength of maximum absorbance at about 313nm, using a spectrophotometer, using the blank solution was measured. Result and discussion The absorbance of Anzol was found to be 0.765 in pH1 and for zantac was 1.099 & in Ph4 it was 3.064 anf for zantac 3.033 on the other hand the a further brand zantac its absorbance in PH6.9 was 3.43 for anzol and zantac 2.177 as shown in Table:2. Consequently, the result of linearity on this study was found to be for Brand Anzol in 200ppm it was 3.43,for zantac it illustrate 2.177. For 100 ppm the value for anzol was 1.8 & 1.083 for zantac likewise for 50ppm it was 0.857 for anzol and 0.6 for zantac therefore our last linearity which was 25ppm bring into being 0.428 for anzol & 0.272 for zantac shown in Table 3. For comparative studies among the two dissimilar brands the SPPS Version 20 was put into practice and there are significant values of P are 0.000 in Ph1 & pH6.9 (p<0.05). Regression was made by the help of Excel and it shows a linear relationship between the two brands shown in Figure 2 & 3. International, Peer reviewed, Open access, Bimonthly Online Journal Journal of Biotechnology and Biosafety Volume 3, Issue 2, March-April 2015,209-213 ISSN 2322-0406 Journal of Biotechnology and Biosafety Table 1: One Way ANOVA between groups and within groups pH1 pH4 pH6.9 Sum of Squares df Mean Square F Sig. Between Groups .214 1 .214 188.445 .000 Within Groups .005 4 .001 Total .218 5 Between Groups .001 1 .001 1.058 .362 Within Groups .002 4 .000 Total .002 5 Between Groups 2.514 1 2.514 1009.263 .000 Within Groups .010 4 .002 Total 2.524 5 Table 2: Absorbance at different Concentrations & Regression Equation Brands pH1 pH4 pH6.9 A 0.765 3.061 3.43 B 1.099 3.033 2.177 Regression y = 0.017x + 0.017 y = 0.010x + 0.025 R² R² = 0.999 R² = 0.999 Table 3: Absorbance at Different ppm Concentration Strength 200ppm 100ppm 50ppm 25ppm www.jobb.co.in Drug A 3.43 1.8 0.857 0.428 Drug B 2.177 1.083 0.6 0.272 International, Peer reviewed, Open access, Bimonthly Online Journal Journal of Biotechnology and Biosafety Volume 3, Issue 2, March-April 2015,209-213 ISSN 2322-0406 Journal of Biotechnology and Biosafety Fig-2: Absorbance of Drug A at different strength Fig-3: Absorbance of Drug B at different strength CONCLUSION: Ranitidine Brands show equivalent results both of A & B in different medium except in pH4 as in this medium it found to be non significant; therefore both Brands are not equal to each other. REFRENCECS: Bergheim M, R.K (2012). Biodegradability and ecotoxicity of tramadol, rantidine and their photoderivaitves in the aquatic environment, Environ, Sci. Pollut. Res.19:72-85 www.jobb.co.in Benet LZ (1991). Safety and pharmacokinetics: colloidal bismuth subcitrate. Scand J Gastroenterol.185:29– 35. [PubMed] International, Peer reviewed, Open access, Bimonthly Online Journal Journal of Biotechnology and Biosafety Volume 3, Issue 2, March-April 2015,209-213 ISSN 2322-0406 Journal of Biotechnology and Biosafety Chung WG, Park CS, Roh HK, Lee WK, Cha YN (2000).Oxidation of ranitidine by isozymes of flavincontaining monooxygenase and cytochrome P450. Jpn J Pharmacol. 84:213–220. [PubMed Flores Pérez J, JuárezOlguín H, Flores Pérez C, Pérez Guillé G, Guillé Pérez A, Camacho Vieyra A, Toledo López A, Carrasco Portugal M, LaresAsseff I (2003). Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int. 20:485–494. [PubMed] Grant SM, Langtry HD, Brogden RN. Ranitidine (1989).An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs.37:801– 870. [PubMed] Higuchi K, Watanabe T, Tominaga K, Shiba M, Nakagawa K, Uno H, Kitada K, Satoh H, Chono S, Uchida T, (2005). Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial. Int ClinPharmacol Res.25:187–194. [PubMed]i J Martínez AJ, CallejoMelgosa A, Fuentes GM, Martín García C (2006). Rhinitis and asthma due to ranitidine. J InvestigAllergolClinImmunol. 16:142–143. [PubMed] Martin H. Kroll and Kenneth Emancipator (1993).A Theoretical Evaluation of Linearity. CLIN.CHEM. 39(3): 405-413 Nwokolo CU, Gavey CJ, Smith JT, Pounder RE (1989). The absorption of bismuth from oral doses of tripotassiumdicitratobismuthate. Aliment PharmacolTher. 3:29–39. [PubMed] Paaaey RB, Bee DE, Caffo A, Erikaon JM (1986). Evaluation of the linearity of quantitative analytical methods; proposed guideline. NCCLS Document EP6-P. Villanova, PA:National Committee for Clinical Laboratory Standards. Pérez-Guillé G, Guillé-Pérez A, Toledo-López A, Juárez-Olguín H, Flores Pérez C, Flores-Pŕez J, Carrasco-Portugal M, Lares-Asseff I, Camacho-Vieyra A(2005). Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers. Proc West Pharmacol Soc. 48:84–88. [PubMed] Hoogerwerf WA, Pasricha PJ (2001). Agents used for control of gastric acidity and treatment of peptic ulcers and gastroesophageal reflux disease. In: Hardman JG, Limbird LE, Goodman Gilman A, ed , editors. The Safila Naveed and Fatima Qamar (2014) Simple UV spectrophotometric assay of Metronidazole Open Access Library Journal, 1: e615:1-4. http://dx.doi.org/10.4236/oalib.1100615 Pharmacological Basis of Therapeutics. New York: McGraw-Hill. 1005–1020. Safila Naveed, Hina Rehman, Fatima Qamar, Syeda Zainab(2015) Method development of Perindopril using UV spectrophotometer (2015) International journal of pharmaceutical Quality Assurance:6(1) http://ijpqa.com/# Citation of this article: Safila Naveed, Fatima Qamar,Syeda Sarah Abbas, ,Sehrish Batool, Syed Hameez Jawed & Syeda Zainab. Accessibility of Altered Trade Names of Ranitidine in different standard by UV Spectrophotometric Technique. Journal of Biotechnology and Biosafety. 3(2):209-213 Source of Support: Nil www.jobb.co.in Conflict of Interest: None Declared International, Peer reviewed, Open access, Bimonthly Online Journal